期刊文献+

幽门螺杆菌培养及药敏试验的临床应用

Clinical application of Hp culture and susceptibility test
原文传递
导出
摘要 [目的]分析山西省吕梁地区幽门螺杆菌(Hp)对该地区5种常用抗生素的耐药率,探讨不同治疗方案对Hp相关性消化性溃疡(PU)治疗的经济效果。[方法]将284例胃黏膜标本进行Hp临床菌株分离培养成功104例,对该地区常用的5种抗生素进行纸片法药敏实验。根据药敏试验结果选取135例Hp阳性的PU患者,随机分成3组。A组45例(奥美拉唑胶囊加阿莫西林胶囊加呋喃唑酮片);B组45例(埃索美拉唑片加阿莫西林胶囊加克拉霉素片);C组45例(枸椽酸铋钾胶囊加阿莫西林胶囊加甲硝唑片)。3组疗程均为4周。观察Hp根除率及溃疡愈合率,运用药物经济学的成本-效果分析(C/E)法对Hp相关性PU的3种治疗方案进行分析评价,比较3种治疗方案对Hp相关性PU治疗的经济效果。[结果]Hp培养阳性率为36.6%,耐药率分别为:甲硝唑片75.3%、克拉霉素片7.4%、阿莫西林胶囊7.4%、左氧氟沙星胶囊12.4%、呋喃唑酮片8.6%。Hp根除率:A、B、C组分别为91.12%、93.33%、51.12%;溃疡愈合率:A、B、C组分别为93.34%、95.56%、42.23%。C/E、增长的成本-效果比分析(△C/△E)及1年内溃疡的复发率调查表明,治疗Hp相关性PU,B组方案最佳。[结论]细菌培养、药敏试验、药物经济学在优化治疗方案、指导合理用药、提高经济效益方面具有重要作用。 [Objective]To analyze the HP's drug resistance rate of 5 major antibiotics and in- quire into the economic effect of the different treatment plans for peptic ulcer relevant to Hp in Lvliang, Shanxi province. [Methods]Samples of gastric mucosa were segregated and cultured in diagnosis of Hp clinical strain. The 104 successful samples were given the susceptibility test by paper disk method to 5 major antibiotics. According to the result of susceptibility test, 135 positive samples of Hp culture were selected and devided into three groups at random: 45samples of A group (Omeprazole + Amoxil+ Furaltadone);45 samples of B group(Astravenbca +Amoxil+ Clarithromycin) ;45 samples of C group(Colloidal bismuth subcitrate + Amoxil + Arilin). The course of treatment on 3 groups were all 4 weeks. The eradicating rate of Hp and coalescence rate of peptic ulcer were observed. Pharmacoeconomics' cost-effect analysis was used to evaluate the three kinds of treatments. [Results]The positive rate of Hp culture was 36.6%. The drug resisitance rate of Arilin was 75. 3%; Clarithromycin 7. 4%; Amoxil 7. 4%; Levofloxacin 12. 4%; Furaltadone 8. 6 %. The eradicating rate of Hp:A group was 91. 12%, B group 93. 33%, C group 51.12%. The coalescence rate of ulcer: A group was 93. 34%, B group 95. 56%, C group 42.23%. The cost effect analysis,the increasing cost-effect analysis (△C/△E)and rearising rate of ulcer in 1 year indicate B group was the best scheme for peptic ulcer relevant to Hp. [Conclusion]Bacterial culture,susceptibility tests, and pharmacoeconomics are very important in optimizing treatment plans, guiding rational drug usage and increasing economic efficiency.
出处 《中国中西医结合消化杂志》 CAS 2008年第5期311-314,共4页 Chinese Journal of Integrated Traditional and Western Medicine on Digestion
关键词 消化性溃疡 幽门螺杆菌 细菌培养 药敏试验 成本-效果分析 Helicobacter Pylori bacterial culture susceptibility test cost-effect analysis
  • 相关文献

参考文献8

二级参考文献30

  • 1张万岱,萧树东,胡伏莲,林三仁,胡品津,刘文忠,王继德,徐智民,成虹.对幽门螺杆菌若干问题共识意见[J].世界华人消化杂志,2004,12(10):2457-2458. 被引量:54
  • 2Malfertheinerl P, Megraud F, O′Morain C, et al. The European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection. The Masstricht 2-2000 Consensus Report [J]. Aliment Pharmacol Ther,2002,16 (2):167-180.
  • 3Wang WH, Wong BCY, Mukhopadhyay AK, et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong [J]. Aliment Pharmacol Ther, 2000,14(7):901-910.
  • 4Megraud F. Basis for the management of drug-resistant Helicobacter pylori infection [J]. Drugs,2004,64(17): 1 893-1 904.
  • 5Gerrits MM, Van der Wouden EJ, Bax DA, et al. Role of the rdxA and frxA genes in oxygen-dependent metronidazole resistance of Helicobacter pylori [J]. J Med Microbiol,2004,53(Pt 11):1 123-1 128.
  • 6Khan R, Nahar S, Sultana J, et al. T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh [J]. Antimicrob Agents Chemother,2004,48(9):3 567-3 569.
  • 7Gerrits MM, Berning M, Van Vliet AH, et al. Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori [J]. Antimicrob Agents Chemother,2003,47(9): 2 984-2 986.
  • 8Kwon DH, Dore MP, Kim JJ, et al. High-level beta-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori [J]. Antimicrob Agents Chemother,2003,47(7): 2 169-2 178.
  • 9Toracchio S, Capodicasa S, Soraja DB, et al. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin [J]. Dig Liver Dis,2005,37(1):33-38.
  • 10Calvet X, Montserrat A, Guell M, et al. Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study [J]. Eur J Gastroenterol Hepatol,2004, 16(10):987-990.

共引文献303

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部